Anaphylactic Reaction to Dulaglutide: A Glucagon Like Peptide- 1 Receptor Agonist

Quadri H, Ataallah B, Haggerty G

Journal of the Endocrine Society3 May 2021

PMCIDPMC8090007PepBankPUB-96021749

Read at source Source pageAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanCase report or seriesSafety outcome
A woman with diabetes developed systemic hypersensitivity after starting dulaglutide, requiring hospitalization and drug discontinuation.
In plain wordsA woman with diabetes had a systemic allergic reaction after dulaglutide and needed hospital care and treatment discontinuation.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableAnaphylactic reaction requiring hospitalization and discontinuation
Study
n = 1
Outcome group
Adverse events · Immune and inflammation
Studied dose
Dose not stated · injectionAs given in this study (human).
Source sentences
Summary
Our patient had anaphylactic reaction after using Dulaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
We report a patient with Type 2 DM who was recently started on Dulaglutide and started to experience systemic hypersensitivity reactions that required discontinuing the medication and inpatient hospitalization.
Report a problemFND-9602174901
02HumanCase report or seriesSafety outcome
A woman with diabetes developed an itchy lip and chin rash within one hour of her first dulaglutide injection.
In plain wordsA woman with diabetes developed an itchy lip and chin rash after her first dulaglutide injection.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableItchy lip and chin rash
Study
n = 1
Outcome group
Adverse events · Immune and inflammation
Studied dose
Dose not stated · injectionAs given in this study (human).
Source sentences
Summary
Case: A 53-Year-old Caucasian female with past medical history of type 2 DM on Metformin presented to the ED with sudden onset of sporadic itchy rash on the lip and chin associated with lip swelling within one hour of her first injection of Dulaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
We report a patient with Type 2 DM who was recently started on Dulaglutide and started to experience systemic hypersensitivity reactions that required discontinuing the medication and inpatient hospitalization.
Report a problemFND-9602174902
03HumanCase report or seriesSafety outcome
A woman with diabetes developed lip swelling within one hour of her first dulaglutide injection.
In plain wordsA woman with diabetes developed swollen lips after her first dulaglutide injection.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableLip swelling
Study
n = 1
Outcome group
Adverse events · Immune and inflammation
Studied dose
Dose not stated · injectionAs given in this study (human).
Source sentences
Summary
Case: A 53-Year-old Caucasian female with past medical history of type 2 DM on Metformin presented to the ED with sudden onset of sporadic itchy rash on the lip and chin associated with lip swelling within one hour of her first injection of Dulaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
We report a patient with Type 2 DM who was recently started on Dulaglutide and started to experience systemic hypersensitivity reactions that required discontinuing the medication and inpatient hospitalization.
Report a problemFND-9602174903
04HumanCase report or seriesSafety outcome
A woman with an allergic reaction after dulaglutide denied difficulty breathing.
In plain wordsA woman with an allergic reaction after dulaglutide reported no breathing difficulty.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableBreathing difficulty
Study
n = 1
Outcome group
Adverse events · Respiratory
Studied dose
Dose not stated · injectionAs given in this study (human).
Source sentences
Summary
She denied difficulty breathing, rash or pruritus on any other part of the body.
1 context sentence(design, population, supporting numbers)
Summary · context
We report a patient with Type 2 DM who was recently started on Dulaglutide and started to experience systemic hypersensitivity reactions that required discontinuing the medication and inpatient hospitalization.
Report a problemFND-9602174904
05HumanCase report or seriesSafety outcome
A woman with an allergic reaction after dulaglutide denied rash or pruritus elsewhere on her body.
In plain wordsA woman with an allergic reaction after dulaglutide reported no rash or itching elsewhere on her body.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableRash or pruritus elsewhere
Study
n = 1
Outcome group
Adverse events · Immune and inflammation
Studied dose
Dose not stated · injectionAs given in this study (human).
Source sentences
Summary
She denied difficulty breathing, rash or pruritus on any other part of the body.
1 context sentence(design, population, supporting numbers)
Summary · context
We report a patient with Type 2 DM who was recently started on Dulaglutide and started to experience systemic hypersensitivity reactions that required discontinuing the medication and inpatient hospitalization.
Report a problemFND-9602174905
06HumanCase report or seriesSafety outcome
A woman with an allergic reaction after dulaglutide improved after treatment and was discharged after 48 hours.
In plain wordsA woman with an allergic reaction after dulaglutide improved after treatment and left hospital after 48 hours.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableRecovery after allergy treatment
Study
n = 1
Outcome group
Adverse events · Immune and inflammation
Studied dose
Dose not stated · injectionAs given in this study (human).
Source sentences
Summary
After 48 hours, the patient’s symptoms were improved and she was discharged home.
2 context sentences(design, population, supporting numbers)
Summary · context
She was treated for her allergic reaction with Intramuscular injection of Epinephrine 0.3mg, Intravenous Dexamethasone 6mg and Intravenous Diphenhydramine 25mg.
Summary · context
We report a patient with Type 2 DM who was recently started on Dulaglutide and started to experience systemic hypersensitivity reactions that required discontinuing the medication and inpatient hospitalization.
Report a problemFND-9602174906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Abstract

PepBank is a research reference. Talk to a doctor before you use any peptide.